Authority: Supreme Court of India

Order Date: 27 July 2026

Case Overview

  • Parties: Sun Pharma Laboratories Limited (appellant) vs. Intas Pharmaceuticals Limited (respondent).
  • Origin: Appeal against the Delhi High Court Division Bench judgment dated 29‑05‑2026 in RFA(OS)(COMM) No.10/2026.
  • Related applications: IA No.199923/2026 (exemption from filing C/C of the impugned judgment) and IA No.199924/2026 (permission to file additional documents/facts/annexures).
  • Counsel: For Sun Pharma – Senior Counsel Shri Mukul Rohatgi, along with a team of advocates; for Intas – Senior Counsel Shri Abhishek Manu Singhvi, Sr. Adv. Shri Amit Sibal and supporting counsel.
  • Bench: Chief Justice Surya Kant, Justice Joymalya Bagchi, Justice V. Mohana.

Observations & Directions

1. Leave to appeal was granted by the Supreme Court.

2. The Court set aside specific paragraphs of the impugned Delhi High Court judgment: paragraph 155(a), paragraph 158, and paragraph 159.

3. The appeal is disposed of in terms of the signed order.

4. All pending applications, if any, including the exemption and permission applications, stand disposed of.

5. The order was signed by CJI Surya Kant and Justices Joymalya Bagchi and V. Mohana.

Final Outcome

  • The Supreme Court partially overturns the Delhi High Court decision by nullifying paragraphs 155(a), 158, and 159, and dismisses the appeal, thereby concluding the litigation. All ancillary applications are also closed.

Topics: Pharma Litigation, Supreme Court Decision